Figure 3From: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvementMean changes from baseline (day 0, pre-infusion) in C-reactive protein (CRP; mg/L).Back to article page